Mechanism of Action
NPSR1 Signaling
NPS binds NPSR1, activating both Gq (PLC/IP3/calcium) and Gs (adenylyl cyclase/cAMP) pathways. In arousal centers including the locus coeruleus and basal forebrain, NPSR1 activation increases norepinephrine and acetylcholine release, promoting wakefulness. In limbic circuits including the amygdala and bed nucleus of the stria terminalis, NPSR1 activation suppresses fear conditioning and reduces CRF-driven anxiety responses.
Arousal Without Anxiety
The simultaneous wakefulness and anxiolysis produced by NPS distinguishes it from all known arousal-promoting drugs. Classical stimulants and wake-promoting agents (modafinil, amphetamine, caffeine) increase anxiety through noradrenergic or adrenergic mechanisms. NPS activates arousal pathways while simultaneously suppressing amygdala fear circuits, achieving a pharmacological profile with no current pharmaceutical equivalent.
Research Summary
Anxiety and Fear Extinction
AnimalICV NPS administration reduced anxiety-like behavior in the elevated plus maze, light-dark box, and open field test across multiple rodent species. NPS also facilitated extinction of conditioned fear responses, suggesting applications in PTSD and phobia treatment. A genetic variant (Asn107Ile) in NPSR1 associated with panic disorder supports the anxiety relevance.
Memory Enhancement
AnimalNPS improved performance in contextual fear conditioning, object recognition, and spatial memory tasks. Memory enhancement was observed at low doses that did not produce overt locomotor activation, suggesting a selective cognitive benefit distinct from general arousal.
Sleep-Wake Regulation
AnimalNPS reduced total sleep time and increased wakefulness in EEG studies without the rebound sleep increase seen with stimulants. The quality of wakefulness appeared normal based on EEG spectral analysis, and cognitive performance during NPS-induced wakefulness was maintained or enhanced.
Calculate your Neuropeptide S dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Arousal / anxiety research | 0.1-10 nmol | Single ICV injection | Intracerebroventricular (animal) |
NPS research is currently limited to animal models using central delivery. Peripherally administered NPS does not readily cross the blood-brain barrier, limiting translation to humans without CNS delivery methods.
Interactions
Safety Profile
Animal studies have not identified significant toxicity at research doses. The central delivery requirement for current NPS formulations limits systemic exposure concerns. No abuse potential has been identified in animal models. Peripheral NPSR1 agonists with CNS penetration are under development and will inform human safety data.
References
- [1]Xu YL, et al. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron. 2004;43(4):487-497.
- [2]Pape HC, et al. Neuropeptide S: a transmitter system in the brain regulating fear and anxiety. Neuropharmacology. 2010.
- [3]Leonard SK, Dwyer JM. Translational neuropsychopharmacology of neuropeptide S. Neuropeptides. 2013.